Pustular mycosis fungoides has a poor outcome: a multicentric clinico-pathological and molecular case series study.


Journal

The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041

Informations de publication

Date de publication:
12 Aug 2024
Historique:
received: 07 05 2024
revised: 29 07 2024
accepted: 08 08 2024
medline: 12 8 2024
pubmed: 12 8 2024
entrez: 12 8 2024
Statut: aheadofprint

Résumé

Mycosis fungoides (MF) has usually an indolent course. However, some patients develop a more aggressive disease and few prognostic parameters have been identified. Isolated cases of pustular MF (pMF) suggest an unfavourable prognosis. We aim to describe the clinico-pathological characteristics and prognostic value of pMF. We retrospectively collected data of all cases of MF with histological pustules diagnosed from 2009 to 2020. The outcomes and clinico-pathological characteristics of pMF at diagnosis (pMFD) were compared to those of a cohort of non-pustular MF (NpMF). 33 pMF (including 22 pMFD) and 86 NpMF cases were included. The median age at diagnosis of pMF was 61 years [IQR=50-75]. The median follow-up of pMFD was 32 months [IQR=14-49]. Clinically, 33% of pMF had pustules. Large-cell transformation (LCT) occurred in 17 cases. pMFD were at a significantly more advanced-stage and more showed LCT at diagnosis than NpMF (50% vs 7%, p<0.001 and 23% vs 0%, p<0.001, respectively). In multivariate Cox analysis, the presence of histological pustule at diagnostic was associated with shorter OS in all patients (HR=13.90, CI95%[2.43-79]; p=0.003), and in early-stage patients (HR=11.09, CI95%[1.56-78.82]; p=0.02). In multivariate Fine and Gray model analysis, pMFD was associated with a higher cumulative incidence of LCT (SHR=13.90, CI95% [2.43-79]; p=0.003) in all patients. Median OS after the occurrence of histological pustules during follow-up of all pMF patients was 37 months, with a five-year OS of 25% (CI95% [0.06-0.5]). pMF often follows an aggressive course, with a high risk of LCT and shorter survival, even for early-stage patients. Histological pustules at diagnostic of MF might represent an independent poor prognostic factor, to be confirmed by further studies. Because pustules are not always clinically identified, histological pustules should be mentioned in pathology reports of MF and prompt discussion of a closer follow-up.

Sections du résumé

BACKGROUND BACKGROUND
Mycosis fungoides (MF) has usually an indolent course. However, some patients develop a more aggressive disease and few prognostic parameters have been identified. Isolated cases of pustular MF (pMF) suggest an unfavourable prognosis.
OBJECTIVES OBJECTIVE
We aim to describe the clinico-pathological characteristics and prognostic value of pMF.
METHODS METHODS
We retrospectively collected data of all cases of MF with histological pustules diagnosed from 2009 to 2020. The outcomes and clinico-pathological characteristics of pMF at diagnosis (pMFD) were compared to those of a cohort of non-pustular MF (NpMF).
RESULTS RESULTS
33 pMF (including 22 pMFD) and 86 NpMF cases were included. The median age at diagnosis of pMF was 61 years [IQR=50-75]. The median follow-up of pMFD was 32 months [IQR=14-49]. Clinically, 33% of pMF had pustules. Large-cell transformation (LCT) occurred in 17 cases. pMFD were at a significantly more advanced-stage and more showed LCT at diagnosis than NpMF (50% vs 7%, p<0.001 and 23% vs 0%, p<0.001, respectively). In multivariate Cox analysis, the presence of histological pustule at diagnostic was associated with shorter OS in all patients (HR=13.90, CI95%[2.43-79]; p=0.003), and in early-stage patients (HR=11.09, CI95%[1.56-78.82]; p=0.02). In multivariate Fine and Gray model analysis, pMFD was associated with a higher cumulative incidence of LCT (SHR=13.90, CI95% [2.43-79]; p=0.003) in all patients. Median OS after the occurrence of histological pustules during follow-up of all pMF patients was 37 months, with a five-year OS of 25% (CI95% [0.06-0.5]).
CONCLUSION CONCLUSIONS
pMF often follows an aggressive course, with a high risk of LCT and shorter survival, even for early-stage patients. Histological pustules at diagnostic of MF might represent an independent poor prognostic factor, to be confirmed by further studies. Because pustules are not always clinically identified, histological pustules should be mentioned in pathology reports of MF and prompt discussion of a closer follow-up.

Identifiants

pubmed: 39133548
pii: 7731771
doi: 10.1093/bjd/ljae312
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Auteurs

Christophe Bontoux (C)

Department of Pathology, Cancer University Institute of Toulouse-Oncopole, University Hospital of Toulouse, 31059 Toulouse, France.
OncoSarc, INSERM U1037, Cancer Research Center in Toulouse, 31000 Toulouse, France.
Laboratory of Clinical and Experimental Pathology, Université Côte d'Azur, Pasteur Hospital, Centre Hospitalier Universitaire de Nice, Biobank BB-0033-00025, 06000 Nice, France.
IRCAN Team 4, Inserm U1081/CNRS 7284, Centre de Lutte Contre le Cancer Antoine Lacassagne, 06000 Nice, France.

Marine Badrignans (M)

Department of Pathology, Assistance Publique - Hôpitaux de Paris, Henri-Mondor Hospital, 94010, Créteil, France.

Sivem Afach (S)

Univ Paris Est Créteil EpiDermE, 94010 Créteil, France.

Emilie Sbidian (E)

Univ Paris Est Créteil EpiDermE, 94010 Créteil, France.
Service de Dermatologie, AP-HP, Hôpital Henri-Mondor, 94010 Créteil, France.

Diana-Laure Mboumba (DL)

INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France.

Saskia Ingen-Housz-Oro (S)

Univ Paris Est Créteil EpiDermE, 94010 Créteil, France.
Service de Dermatologie, AP-HP, Hôpital Henri-Mondor, 94010 Créteil, France.

Alexis Claudel (A)

Department of Immunology and Biology, APHP, Henri Mondor hospital, 94000 Creteil, France, Paris-Est Creteil University and INSERM U955 team NFL, 94010 Creteil, France.

Marie-Hélène Aubriot-Lorton (MH)

Service de Pathologie, CHU François Mitterrand, 21000 Dijon, France.

Arnaud Chong-Si-Tsaon (A)

Service de Pathologie, CHU Felix Guyon, 97405 Saint-Denis, France.

Gilles Le Masson (G)

Service de Pathologie, CHRU BREST, 29609 Brest, France.

Christophe Attencourt (C)

Service de Pathologie, Hôpital Nord, 80054 Amiens, France.

Romain Dubois (R)

Service de Pathologie, CHRU Claude Huriez, 59037 Lille, France.

Fanny Beltzung (F)

Service de Pathologie, CHU Bordeaux, Hôpital Haut-Lévèque, 33600 Pessac, France.

Wafa Koubaa (W)

Service de Pathologie, Hôpital Habib Thameur, 1008 Tunis, Tunisie.

Helmut Beltraminelli (H)

Universitätsklinik Für Dermatologie, 3010 Bern, Switzerland.

Nathalie Cardot-Leccia (N)

Laboratoire central d'anatomie et cytologie pathologiques, Hôpital Pasteur, CHU de Nice, 06000, Nice, France.

Brigitte Balme (B)

Service de Pathologie, Lyon Sud, Pierre-Bénite Hospital, 69495, Lyon, France Hospices Civils de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Centre of Lyon, Lyon, France.

Anh Tuan Nguyen (AT)

Service de Pathologie, Hôpital D'Instruction des Armées Bégin, 94160, Saint Mandé, France.

Kelly Bagny (K)

Service de Dermatologie, CHU Felix Guyon, 97405 Saint-Denis, France.

Delphine Legoupil (D)

Service de Dermatologie, CHRU BREST, 29609 Brest, France.

Ibtissam Moustaghfir (I)

Service de Dermatologie, Hôtel-Dieu, 44093 Nantes, France.

Juliette Denamps (J)

Service de Dermatologie, Hôpital Nord, 80054 Amiens, France.

Laurent Mortier (L)

Service de Dermatologie, CHRU Claude Huriez, 59037 Lille, France.

Houda Hammami-Ghorbel (H)

Service de Dermatologie, Hôpital Habib Thameur, 1008 Tunis, Tunisia.

Sergey Skrek (S)

Département De Dermatologie Et De Vénérologie, 194291 Saint-Pétersbourg, Russia.

Mostefa Rafaa (M)

Service De Dermatologie, CH Sud-Francilien, 91106 Corbeil Essonnes, France.

Anne-Claire Fougerousse (AC)

Service de Dermatologie, Hôpital D'Instruction des Armées Bégin, 94160, Saint Mandé, France.

Thibaut Deschamps (T)

Service De Dermatologie, CH Valence, 26953 Valence, France.

Stéphane Dalle (S)

Service de Dermatologie, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Centre of Lyon, Lyon, France.

Michel D'incan (M)

Service de Dermatologie et Oncologie cutanée, CHU de Clermont-Ferrand - Hôpital d'Estaing, 63003 Clermont-Ferrand, France.

Guillaume Chaby (G)

Service de Dermatologie, Hôpital Nord, 80054 Amiens, France.

Marie Beylot-Barry (M)

Service de Dermatologie, CHU de Bordeaux, Saint-André Hospital, 33000, Bordeaux, France.

Sophie Dalac (S)

Services de Dermatologie, CHU François Mitterrand, 21000 Dijon, France.

Nicolas Ortonne (N)

Department of Pathology, Assistance Publique - Hôpitaux de Paris, Henri-Mondor Hospital, 94010, Créteil, France.
INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France.

Classifications MeSH